Development of acute myeloid leukemia in transgenic and knock-in animals. (A) Kaplan-Meier probability of leukemia-free survival of wild-type (CG+/+; ▪), mCG+/PR (+PGK-neo; g▾), and mCG+/PR (ΔPGK-neo; ▴) animals is plotted against time and is compared with leukemia-free survival of a simultaneous cohort of hCG–PML-RARα animals from line no. 134 (the same data were used in Pollock et al6 ; ♦). The number of mice in each cohort was as follows: CG+/+ = 25; mCG+/PR (+PGK-neo) = 26; mCG+/PR (ΔPGK-neo) = 118; hCG-PR = 27. (B) Kaplan-Meier probability of leukemia-free survival of heterozygous mCG+/PR (ΔPGK-neo; ▪) versus homozygous (mCGPR/PR; ▴) animals is plotted against time. The difference between the curves is statistically significant (P = .002). mCG+/PR (ΔPGK-neo) = 118 mice; mCGPR/PR (ΔPGK-neo) = 99 mice. (C) Kaplan-Meier probability of leukemia-free survival of animals carrying a single PML-RARα gene copy together with either an intact CG gene (CG+/PR; ▴) or a null mutation (CG–/PR; ▪) at the other allele is plotted against time. The differences between the curves are not statistically significant (P = .48). mCG+/PR (ΔPGK-neo) = 60 mice; mCG–/PR (ΔPGK-neo) = 71 mice.
